10 recruiting, 9 unknown, 2 terminated, 1 completed. 10 Phase 1, 10 Phase 2, 3 Early Phase 1, 3 Not applicable, 1 Phase 4.
Follow Non-hodgkin Lymphoma,B Cell: new trials by email Literature Review of Non-hodgkin Lymphoma,B Cell trials Research Report on Non-hodgkin Lymphoma,B Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL Allogenic CD19-CAR-γδT cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-07-27 | 2025-07-30 |
| Universal CAR-T Cell Therapy for NHL BRL-301 - Non-hodgkin Lymphoma,B Cell | Not applicable | Recruiting | Bioray Laboratories | 6 | 2025-03-11 | 2025-11-25 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research Metabolically Armed CD19 CAR-T cells - Non-hodgkin Lymphoma,B Cell | Early Phase 1 | Recruiting | Zhejiang University | 36 | 2024-12-01 | 2024-12-04 |
| CAR T-cell Therapy in Patients With Renal Dysfunction Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell, Multiple Myeloma | Phase 2 | Recruiting | Northside Hospital, Inc. | 20 | 2024-11-18 | 2026-10-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL CD19-BAFF Targeted CAR T-cells - Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell | Early Phase 1 | Recruiting | Zhejiang University | 20 | 2024-05-30 | 2024-05-14 |
| SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project Chimeric Antigen Receptor T-cells (CAR-T) therapy - Non-hodgkin Lymphoma,B Cell | Recruiting | Fondazione Italiana Linfomi - ETS | 130 | 2024-04-18 | 2025-12-08 | |
| Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Allogeneic CD19-STAR T cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2024-03-20 | 2024-03-25 |
| The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) CART-19 and 20 cells, Cyclophosphamide, Fludarabine - Non-hodgkin Lymphoma,B Cell | Not applicable | Unknown | Henan Cancer Hospital | 20 | 2023-10-31 | 2023-12-07 |
| TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 38 | 2023-06-30 | 2023-07-06 |
| The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma CD19-targeted non-viral PD1 site-specific integrated CAR-T cell injection - Non-hodgkin Lymphoma,B Cell | Phase 1 | Recruiting | Bioray Laboratories | 18 | 2023-04-25 | 2025-11-25 |
| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine - Non-hodgkin Lymphoma,B Cell, Burkitt Lymphoma | Phase 4 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 300 | 2022-05-25 | 2022-08-26 |
| Immune Response After SARS-CoV-2 (COVID-19) Vaccination in a Context of Non-Hodgkin Lymphoma Immunological analyses - Non-hodgkin Lymphoma,B Cell, Vaccination Failure | Not applicable | Terminated | Versailles Hospital | 120 | 2021-11-15 | 2026-05-06 |
| Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Azacytidine, Bendamustine and Piamprizumab - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2021-04-22 | 2021-05-21 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Allogeneic CD19 CR-T cell - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-03 |
| A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Humanized CD19 CAR-T cells - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | Early Phase 1 | Unknown | Zhejiang University | 72 | 2020-08-23 | 2020-08-31 |
| Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas Lenalidomide - Non-hodgkin Lymphoma,B Cell | Unknown | Ruijin Hospital | 1000 | 2019-11-01 | 2020-07-07 | |
| Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Acalabrutinib - Non-hodgkin Lymphoma,B Cell | Phase 2 | Completed | Seoul National University Hospital | 66 | 2019-07-09 | 2023-04-18 |
| Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy CD19-TriCAR-T - Non-hodgkin Lymphoma,B Cell | Phase 1 | Unknown | Timmune Biotech Inc. | 6 | 2018-11-01 | 2019-12-09 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
Showing 20 of 22. Sign in to see all of them.
Lymphoma, Non-Hodgkin (5) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell (2) · Lymphoma, Mantle-Cell (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Multiple Myeloma (1) · Pyloric Stenosis, Hypertrophic (1) · Recurrence (1) · Sarcopenia (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Lymphoma (9) · Hematologic Diseases (4) · Lymphoma, Non-Hodgkin (4) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Leukemia (2)
Cyclophosphamide (6) · fludarabine (5) · Injections (3) · fludarabine phosphate (3) · Lenalidomide (2) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Carmustine (1) · Cytarabine (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Gemcitabine (1) · Idarubicin (1) · Ifosfamide (1)
Chinese PLA General Hospital (5) · Zhejiang University (3) · Bioray Laboratories (2) · Timmune Biotech Inc. (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Fondazione Italiana Linfomi - ETS (1) · Henan Cancer Hospital (1) · Molecular Templates, Inc. (1) · Northside Hospital, Inc. (1) · Ruijin Hospital (1) · Seoul National University Hospital (1) · Shenzhen University General Hospital (1) · Verismo Therapeutics (1) · Versailles Hospital (1)
China (15) · United States (3) · France (1) · Italy (1) · Russia (1) · South Korea (1)
Haifeng Lin (1) · He Huang, MD (1) · Laura A Johnson, PhD (1) · Li Yu, Dr (1) · Ming Zhou (1) · Vittorio Ruggero Zilioli (1) · Wei Li (1) · Weidong Han, Ph.D (1) · Zhihua Yao, M.D. Ph.D (1)
PMID 28129122, PMID 28925994, PMID 36808074, PMID 37192741, PMID 38555311, PMID 39902042